Insights Into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism of mice and man

Circulation

Volumn 127, Issue 24, 2013, Pages 2372-2374

  Stein, Evan A ^a   Raal, Frederick J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Editorials; Human; Lipid metabolism; Low density lipoprotein cholesterol; PCSK9 protein

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PCSK9 PROTEIN; PLACEBO; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADRENAL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIET THERAPY; DOSE RESPONSE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL;

EDITORIALS; LIPID METABOLISM; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN;

ANIMALS; CHOLESTEROL; HUMANS; MALE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84879305939     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003360     Document Type: Editorial

References (12)

1. Abifadel M, Varret M, Rabès JP, Allard D., Ouguerram K, Devillers M, Cruaud C., Benjannet S, Wickham L, Erlich D., Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
2. Peterson AS, Fong LG, Young SG PCSK9 function and physiology. J Lipid Res. 2008;49:1152-1156.
3. Tavori H, Fan D, Blakemore J.L., Yancey PG, Ding L, Linton MF, Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127:2403-2413.
4. Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K., Berge KE, Leren T P. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein con-vertase subtilisin/kexin type 9 is cleared from plasma by low-density lipo-protein receptor-independent pathways. Transl Res. 2012;160:125-130.
5. Raal F, Panz V, Immelman A., Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercho- lesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013;2:e000028.
6. Sun H, Samarghandi A, Zhang N., Yao Z, Xiong M, Teng BB Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipopro-tein receptor. Arterioscler Thromb Vasc Biol. 2012;32:1585-1595.
7. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297-306.
8. Stein EA, Gipe D, Bergeron J., Gaudet D, Weiss R, Dufour R., Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
9. Roth EM, McKenney JM, Hanotin C, Asset G., Stein EA Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-1900.
10. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterol-emia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
11. Stein EA, Dufour R, Gagne C., Gaudet D, East C, Donovan J.M., Chin W., Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, doubleblind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283-2292.
12. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106-107.